ing the CO PD value at 90% target.
Results:The MIC 50 and MIC 90 were 16 and 32 μg/mL, respectively and epidemiological cut-off value was 128 μg/mL which encompassed 95% of the WT isolates. The growth curves in vitro and ex vivo produced concentration-dependent activity against A. pleuropneumoniae. For PK analysis, C max of healthy and diseased was 9.36 ± 1.60 and 7.69 ± 2.70 μg/mL, respectively, which reached at 0.58 ± 0.24 and 0.69 ± 0.60 h. The MRT of lincomycin in healthy pigs (3.61 ± 0.72 h) was higher than in diseased pigs (93.32 ± 0.61 h), indicating lincomycin eliminated slowly in healthy pigs. The AUC 24 h /MIC based on model of E max inhibitory sigmoid for bacteriostatic and bactericidal activity in plasma was 1.95 and 2.75 h for healthy pigs and 2.45 and 4.3 h for diseased pigs. Rational dosages for bacteriostatic and bactericidal using MCS was calculated as 29.89 mg/kg for 50% target and 39.94 mg/kg for 90% target, respectively in diseased pigs.The CO PD for lincomycin against A. pleuropneumoniae was 16 μg/mL in diseased pigs.
Conclusions:The findings of present study demonstrated that IM administration with a single dose of 39.94 mg/kg to diseased pigs could have bactericidal activity against A. pleuropneumoniae. However, it should be validated in clinical practice for evaluating the effective treatment of A. pleuropneumoniae.